Sphingosine 1-phosphate receptor 1 (S1P(1)) is a G protein-coupled receptor that is critical for proper lymphocyte development and recirculation. Agonists to S1P(1) are currently in use clinically for the treatment of multiple sclerosis, and these drugs may act on both S1P(1) expressed on lymphocytes and S1P(1) expressed within the central nervous system. Agonists to S1P(1) and deficiency in S1P(1) both cause lymphocyte sequestration in the lymph nodes. In the present study, we show that S1P(1) antagonism induces lymphocyte sequestration in the lymph nodes similar to that observed with S1P(1) agonists while upregulating S1P(1) on lymphocytes and endothelial cells. Additionally, we show that S1P(1) antagonism reverses experimental autoimmune encephalomyelitis in mice without acting on S1P(1) expressed within the central nervous system, demonstrating that lymphocyte sequestration via S1P(1) antagonism is sufficient to alleviate autoimmune pathology.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3558813 | PMC |
| http://dx.doi.org/10.1124/mol.112.082958 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of Sphingosine-1-Phosphate on the Facilitation of Peripheral Nerve Regeneration.
Cureus
November 2024
Division of Dental Anesthesiology, Faculty of Dentistry & Graduate School of Medical and Dental Sciences, Niigata University, Niigata, JPN.
This study aims to explore the role of sphingosine-1-phosphate (S1P) in peripheral nerve regeneration after injury. S1P is a crucial metabolite involved in cell migration, inflammation, and nerve regeneration. In this research, six-week-old male Sprague-Dawley rats (total n=18) underwent transection of the inferior alveolar nerve (IAN) and were divided into three groups: S1PR agonist (FTY720) (n=6), saline control (n=6), and S1P1R antagonist (n=6).
View Article and Find Full Text PDFCenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trial.
Lancet Rheumatol
January 2025
Idorsia Pharmaceuticals, Allschwil, Switzerland.
Background: Sphingosine-1-phosphate (S1P) is a signalling molecule that has an inhibitory role in atherosclerosis, inflammation, cell proliferation, and immunity. Cenerimod is a selective S1P receptor modulator under investigation for the treatment of systemic lupus erythematosus (SLE). We aimed to determine the efficacy, safety, and tolerability of four doses of cenerimod in adults with moderate-to-severe SLE receiving standard of care background therapy.
View Article and Find Full Text PDFPharmacodynamics of the S1P receptor modulator cenerimod in a phase 2b randomised clinical trial in patients with moderate to severe SLE.
Ann Rheum Dis
November 2024
Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland
Article Synopsis
- * In a phase 2b trial (CARE), the effects of cenerimod dosages (2mg and 4mg) were evaluated in SLE patients, focusing on gene expression related to interferon and plasma cells after 6 months of treatment.
- * Results indicated that the 4mg dosage of cenerimod significantly decreased interferon-associated biomarkers, especially in patients with high baseline interferon levels, supporting its selection for
Unique pharmacological properties of etrasimod among S1P receptor modulators.
FEBS Open Bio
November 2024
Arena Pharmaceuticals, San Diego, CA, USA.
Etrasimod (ADP334) is an oral, once-daily, selective sphingosine 1-phosphate (S1P) receptor modulator for the treatment of moderately to severely active ulcerative colitis and in development for the treatment of immune-mediated inflammatory diseases. Interaction between S1P and its five receptor subtypes (S1P-S1P) plays a role in several physiologic systems, including the cardiovascular and immune systems. Since differences in S1PR binding and downstream intracellular signaling could contribute to distinct profiles of drug efficacy and safety, we directly compared the S1P selectivity profile of etrasimod to three marketed S1PR modulators: fingolimod, ozanimod, and siponimod.
View Article and Find Full Text PDFTherapeutic Potential of Etrasimod in the Management of Moderately-to-Severely Active Ulcerative Colitis: Evidence to Date.
Clin Exp Gastroenterol
November 2024
Houston Methodist Gastroenterology Associates, Houston Methodist, Houston, TX, USA.
Etrasimod is a sphingosine 1 phosphate (S1P) receptor modulator approved for the treatment of moderate to severely active ulcerative colitis (UC). Etrasimod selectively activates S1P receptors with no detectable activity on S1P. The ELEVATE clinical trials evaluated the efficacy and safety of etrasimod for UC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!